MAC vs NBIX · rev $918.2M vs P/E 45, rev $2.36B
Macerich Company (MAC) versus Neurocrine Biosciences Inc (NBIX) — a side-by-side from cached financials, not a winner call.
Macerich Company (MAC) is a reit - retail company listed on US.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
Latest reported MAC revenue for 2024-12-31 was $918.2M. Net income was -$197.7M. Revenue was up 3.9% from 2023-12-31 to 2024-12-31. MAC currently screens at market cap $4.41B.
Latest reported NBIX revenue for 2024-12-31 was $2.36B. Net income was $341.3M. Revenue was up 24.8% from 2023-12-31 to 2024-12-31. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
MAC currently screens at market cap $4.41B. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Not investment advice. Open the MAC and NBIX stock pages for the full models.
Not investment advice.